Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Preferred Stock Liabilities (2018)

Historic Preferred Stock Liabilities for Bicycle Therapeutics (BCYC) over the last 1 years, with Q4 2018 value amounting to $54.6 million.

  • Bicycle Therapeutics' Preferred Stock Liabilities changed N/A to $54.6 million in Q4 2018 from the same period last year, while for Dec 2018 it was $54.6 million, marking a year-over-year change of. This contributed to the annual value of $54.6 million for FY2018, which is 0.0% changed from last year.
  • Per Bicycle Therapeutics' latest filing, its Preferred Stock Liabilities stood at $54.6 million for Q4 2018.
  • Bicycle Therapeutics' Preferred Stock Liabilities' 5-year high stood at $54.6 million during Q2 2018, with a 5-year trough of $54.6 million in Q2 2018.